临床参数能否反映感染性或无菌性全髋关节置换术后异位骨化的局部骨代谢
本研究在德国两家三级中心回顾性纳入40例翻修全髋关节置换术患者的异位骨化标本,用显微CT和组织形态计量学分析局部骨代谢,并与股骨颈骨小梁及骨赘对照。结果显示感染性与无菌性异位骨化均表现为持续活跃的骨塑建与重塑,常规临床、血清及滑液指标无法推断局部骨代谢,翻修前使用非甾体抗炎药仅与骨样组织厚度增加相关。
要点
- 感染性与无菌性异位骨化均显示骨体积分数升高、骨密度降低及持续骨塑建。
- 骨细胞密度仅在感染性异位骨化中升高,提示两种异位骨化的稳态机制不同。
- 常规临床、血清和滑液指标不能用于推断异位骨化的局部骨代谢。
核心结论
- 无菌性和感染性异位骨化在骨代谢持续增高方面具有相似表型特征,但骨细胞和脂肪细胞数量的差异提示稳态机制不同。
- 这些结果提示存在持续的骨塑建或重塑,无菌性异位骨化中成骨细胞和破骨细胞指标随原位时间呈中度下降。
- 未来研究应采用纵向设计将本研究发现与临床结局(如异位骨化生长或复发)相关联,并进一步研究异位骨化形成和生长过程中骨细胞参与的分子机制,以制定特异性治疗和预防干预措施。
研究设计与样本
- 回顾性比较研究,于2021年6月至2022年5月在德国两家三级中心筛查395例接受翻修全髋关节置换术的患者。
- 符合影像学异位骨化者占21%(83/395),进一步排除43例后,最终10%(40例)纳入分析。
- 无菌性翻修25例(男18例、女7例,平均年龄70±11岁,平均BMI 29±4 kg/m²),感染性翻修15例(男11例、女4例,平均年龄69±9岁,平均BMI 32±9 kg/m²),距初次植入平均6±7年,翻修时平均年龄70±9岁。
- 感染源(假体周围关节感染)依据2018年国际共识会议标准通过术前血清和滑液参数评估诊断。
- 对照取自股骨颈骨小梁(10例:女5例、男5例,平均年龄75±6岁,平均BMI 28±4 kg/m²)和骨赘(10例:女5例、男5例,平均年龄70±10岁,平均BMI 29±7 kg/m²)。
主要发现
- 与股骨颈标本相比,无菌性和感染性异位骨化均表现为更高的骨体积分数(无菌性:0.41±0.15,平均差0.20[95%CI 0.07至0.32];感染性:0.43±0.15,平均差0.22[95%CI 0.08至0.36];股骨颈:0.21±0.04;均p<0.001)。
- 与股骨颈标本相比,无菌性和感染性异位骨化均表现为更低的骨矿物质密度(无菌性:809±66 mg HA/cm³,平均差-91 mg HA/cm³[95%CI -144至-38];感染性:789±44 mg HA/cm³,平均差-111 mg HA/cm³[95%CI -169至-53];股骨颈:899±20 mg HA/cm³;均p<0.001)。
- 与股骨颈标本相比,无菌性和感染性异位骨化均存在持续的骨塑建伴软骨内成骨及更高比例的编织未成熟骨(无菌性:25%±17%,平均差25%[95%CI 9%至41%];感染性:37%±23%,平均差36%[95%CI 19%至54%];股骨颈:0.4%±0.5%;均p<0.001)。
- 无菌性和感染性异位骨化的骨表面均表现为成骨细胞和破骨细胞指数增加,但骨细胞密度升高仅见于感染性异位骨化(无菌性:158±56 1/mm² vs 感染性:272±48 1/mm²,平均差114 1/mm²[95%CI 65至162];p<0.001)。
- 与骨赘相比,异位骨化的微结构和骨转换指标基本相似;Brooker分级与任何局部骨代谢参数均无关联;原位时间与无菌性异位骨化的骨转换呈负相关(成骨细胞表面积/骨表面积:r=-0.46;p=0.01;破骨细胞表面积/骨表面积:r=-0.56;p=0.003);血清或滑液炎症标志物与感染性异位骨化的局部骨转换无相关性。
关键数值与推荐
- 感染性异位骨化诊断依据2018年国际共识会议标准,通过术前血清和滑液参数评估。
- 异位骨化严重度采用Brooker分级评估。
临床怎么用
- 据作者所知,本研究首次系统研究全髋关节置换术后异位骨化患者的组织形态计量学骨代谢参数,为评估骨塑建和重塑活动提供临床参考。
- 常规临床、血清和滑液标志物不能用于推断局部骨代谢。
局限性
- 未来研究应采用纵向研究设计将本研究发现与临床结局(如异位骨化生长或复发)相关联。
- 异位骨化形成和生长过程中骨细胞参与的分子机制应进一步研究,以制定特异性治疗和预防干预措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heterotopic ossification (HO) is a common complication after THA. Although current research primarily focuses on treatment and prevention, little is known about the local bone metabolism of HO and clinical contributing factors. QUESTIONS/PURPOSES: We aimed to assess bone remodeling processes in HO using histomorphometry, focusing on the effects of inflammation and prior NSAID treatment. Specifically, we asked: (1) Are HO specimens taken from patients with periprosthetic joint infection (PJI) more likely to exhibit active bone modeling and remodeling than specimens taken at the time of revision from patients without infection? (2) Do clinical or inflammatory serum and synovial parameters reflect the microstructure of and remodeling in both HO entities? (3) Is NSAID treatment before revision surgery associated with altered local bone mineralization or remodeling properties? METHODS: Between June 2021 and May 2022, we screened 395 patients undergoing revision THA at two tertiary centers in Germany. Of those, we considered all patients with radiographic HO as potentially eligible. Based on that, 21% (83 of 395) were eligible; a further 43 were excluded because of an inability to remove the implant intraoperatively (16 patients), insufficient material (11), comorbidities with a major effect on bone metabolism (10), or bone-specific drugs (six), leaving 10% (40) for analysis in this retrospective, comparative study. HO specimens were collected during aseptic (25 patients: 18 male, seven female, mean age 70 ± 11 years, mean BMI 29 ± 4 kg/m 2 ) and septic (15 patients: 11 male, four female, mean age 69 ± 9 years, mean BMI 32 ± 9 kg/m 2 ) revision THA at a mean of 6 ± 7 years after primary implantation and a mean age of 70 ± 9 years at revision. Septic origin (PJI) was diagnosed based on the 2018 International Consensus Meeting criteria, through a preoperative assessment of serum and synovial parameters. To specify the local bone microstructure, ossification, and cellular bone turnover, we analyzed HO specimens using micro-CT and histomorphometry on undecalcified sections. Data were compared with those of controls, taken from femoral neck trabecular bone (10 patients: five female, five male, mean age 75 ± 6 years, mean BMI 28 ± 4 kg/m 2 ) and osteophytes (10 patients: five female, five male, mean age 70 ± 10 years, mean BMI 29 ± 7 kg/m 2 ). The time between primary implantation and revision (time in situ), HO severity based on the Brooker classification, and serum and synovial markers were correlated with HO microstructure and parameters of cellular bone turnover. In a subgroup of specimens of patients with NSAID treatment before revision, osteoid and bone turnover indices were evaluated and compared a matched cohort of specimens from patients without prior NSAID treatment. RESULTS: Patients with aseptic and septic HO presented with a higher bone volume (BV/TV; aseptic: 0.41 ± 0.15, mean difference 0.20 [95% CI 0.07 to 0.32]; septic: 0.43 ± 0.15, mean difference 0.22 [95% CI 0.08 to 0.36]; femoral neck: 0.21 ± 0.04; both p < 0.001), lower bone mineral density (aseptic: 809 ± 66 mg HA/cm 3 , mean difference -91 mg HA/cm 3 [95% CI -144 to -38]; septic: 789 ± 44 mg HA/cm 3 , mean difference -111 mg HA/cm 3 [95% CI -169 to -53]; femoral neck: 899 ± 20 mg HA/cm 3 ; both p < 0.001), and ongoing bone modeling with endochondral ossification and a higher proportion of woven, immature bone (aseptic: 25% ± 17%, mean difference 25% [95% CI 9% to 41%]; septic: 37% ± 23%, mean difference 36% [95% CI 19% to 54%]; femoral neck: 0.4% ± 0.5%; both p < 0.001) compared with femoral neck specimens. Moreover, bone surfaces were characterized by increased osteoblast and osteoclast indices in both aseptic and septic HO, although a higher density of osteocytes was detected exclusively in septic HO (aseptic: 158 ± 56 1/mm 2 versus septic: 272 ± 48 1/mm 2 , mean difference 114 1/mm 2 [95% CI 65 to 162]; p < 0.001). Compared with osteophytes, microstructure and turnover indices were largely similar in HO. The Brooker class was not associated with any local bone metabolism parameters. The time in situ was negatively associated with bone turnover in aseptic HO specimens (osteoblast surface per bone surface: r = -0.46; p = 0.01; osteoclast surface per bone surface: r = -0.56; p = 0.003). Serum or synovial inflammatory markers were not correlated with local bone turnover in septic HO. Specimens of patients with NSAID treatment before revision surgery had a higher osteoid thickness (10.1 ± 2.1 µm versus 5.5 ± 2.6 µm, mean difference -4.7 µm [95% CI -7.4 to -2.0]; p = 0.001), but there was no difference in other osteoid, structural, or cellular parameters. CONCLUSION: Aseptic and septic HO share phenotypic characteristics in terms of the sustained increase in bone metabolism, although differences in osteocyte and adipocyte numbers suggest distinct homeostatic mechanisms. These results suggest persistent bone modeling or remodeling, with osteoblast and osteoclast indices showing a moderate decline with the time in situ in aseptic HO. Future studies should use longitudinal study designs to correlate our findings with clinical outcomes (such as HO growth or recurrence). In addition, the molecular mechanisms of bone cell involvement during HO formation and growth should be further investigated, which may allow specific therapeutic and preventive interventions. CLINICAL RELEVANCE: To our knowledge, our study is the first to systematically investigate histomorphometric bone metabolism parameters in patients with HO after THA, providing a clinical reference for evaluating modeling and remodeling activity. Routine clinical, serum, and synovial markers are not useful for inferring local bone metabolism.
引用
- von Kroge S, Büyükyilmaz Z, Alimy AR, et al. Do Clinical Parameters Reflect Local Bone Metabolism in Heterotopic Ossification After Septic or Aseptic THA? Clin Orthop Relat Res. 2023. PMID: 37462509. doi:10.1097/CORR.0000000000002758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。